| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2004.10.142 |
| P698 | PubMed publication ID | 15197207 |
| P50 | author | Nita L Seibel | Q89543834 |
| Stephanie L Safgren | Q92977647 | ||
| P2093 | author name string | Joel M Reid | |
| Matthew M Ames | |||
| Mark D Krailo | |||
| John Kuttesch | |||
| Wenchun Qu | |||
| John Holcenberg | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| phase I clinical trial | Q5452194 | ||
| P304 | page(s) | 2445-2451 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors | |
| P478 | volume | 22 |
| Q38961012 | A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials |
| Q64053792 | A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML |
| Q52981912 | A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control. |
| Q48037657 | Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. |
| Q33773101 | Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment |
| Q33379627 | Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma |
| Q47882998 | Establishing A Preclinical Multidisciplinary Board for Brain Tumors. |
| Q35047386 | Folate-chitosan-gemcitabine core-shell nanoparticles targeted to pancreatic cancer |
| Q33399473 | Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas |
| Q45737971 | Gemcitabine induced skin rash |
| Q37955222 | Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. |
| Q79956606 | Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy |
| Q37118947 | Histone deacetylase inhibitors in lymphoma and solid malignancies |
| Q34819537 | In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles |
| Q83389944 | Integrating pharmacogenetics into gemcitabine dosing--time for a change? |
| Q91949972 | Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma |
| Q31098128 | Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells |
| Q34988879 | Modular polymer-caged nanobins as a theranostic platform with enhanced magnetic resonance relaxivity and pH-responsive drug release |
| Q33273430 | Multidisciplinary management of primary tumors of the vertebral column |
| Q36616537 | New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children |
| Q89736510 | Novel Hyaluronic Acid Conjugates for Dual Nuclear Imaging and Therapy in CD44-Expressing Tumors in Mice In Vivo |
| Q35135650 | Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma |
| Q37048013 | Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency |
| Q97543068 | Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine |
| Q35610203 | Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. |
| Q33409922 | Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo |
Search more.